Thyroid Cancer News and Research RSS Feed - Thyroid Cancer News and Research

Thyroid Cancer is cancer that forms in the thyroid gland (an organ at the base of the throat that makes hormones that help control heart rate, blood pressure, body temperature, and weight). Four main types of thyroid cancer are papillary, follicular, medullary, and anaplastic thyroid cancer. The four types are based on how the cancer cells look under a microscope.
Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). [More]
Highmark, Horizon issued positive coverage policies for Afirma Gene Expression Classifier

Highmark, Horizon issued positive coverage policies for Afirma Gene Expression Classifier

Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that two Blue Cross Blue Shield–affiliated organizations, Highmark Inc. and Horizon Blue Cross Blue Shield of New Jersey, have issued positive coverage policies for the company's Afirma Gene Expression Classifier (GEC). [More]
People with significant hypothyroidism can experience impaired driving

People with significant hypothyroidism can experience impaired driving

People with significant hypothyroidism can experience impaired driving similar to those who are driving when intoxicated by alcohol, a new study finds. [More]
Experts from 96 countries gather in Chicago to attend ICE/ENDO 2014

Experts from 96 countries gather in Chicago to attend ICE/ENDO 2014

ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, has tallied more registrants than any other annual meeting in the Endocrine Society's nearly 100-year history. [More]
Research to identify new potential targets for cancer therapy

Research to identify new potential targets for cancer therapy

In 2012, about 8.2 million people died of cancer making the disease a major cause of death worldwide. According to the WHO World Cancer Report 2014, this figure is expected to rise within the next two decades. [More]
Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). [More]
Space Station science: Microgravity on human thyroid carcinoma cells

Space Station science: Microgravity on human thyroid carcinoma cells

The multi-national efforts that go into research aboard the International Space Station show that working together can yield results with universal benefits. [More]
Veracyte's revenue increases 71% to $7.5 million in Q1 2014

Veracyte's revenue increases 71% to $7.5 million in Q1 2014

Veracyte, Inc. today reported financial results for the first quarter ended March 31, 2014, and provided an update on recent business progress. For the first quarter of 2014, revenue was $7.5 million, an increase of 71%, compared to $4.4 million for the first quarter of 2013. [More]
ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments. [More]
Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease. [More]
First Edition: March 31, 2014

First Edition: March 31, 2014

Today's early morning highlights from the major news organizations offer assessments of the administration's campaign to get people signed up for health care and a look at the issues going forward after today's deadline for most enrollments. [More]
Scientists discover new protein that drive metastasis of cancer cells

Scientists discover new protein that drive metastasis of cancer cells

An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body. [More]
Young adults with secondary thyroid cancer may have greater risk of dying than those with primary cancer

Young adults with secondary thyroid cancer may have greater risk of dying than those with primary cancer

A new analysis has found that adolescents and young adults who develop thyroid cancer as a secondary cancer have a significantly greater risk of dying than those with primary thyroid cancer. [More]
Researchers discover protein for treatment of anaplastic thyroid carcinoma

Researchers discover protein for treatment of anaplastic thyroid carcinoma

Anaplastic thyroid carcinoma (ATC) is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore (NUS) have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC. [More]
NUS researchers discover promising treatment for anaplastic thyroid carcinoma

NUS researchers discover promising treatment for anaplastic thyroid carcinoma

Anaplastic thyroid carcinoma is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC. [More]
New comprehensive textbook on tiny parathyroid glands for endocrine surgeons

New comprehensive textbook on tiny parathyroid glands for endocrine surgeons

How robots enable no-neck-scar thyroid surgery and advanced imaging helps surgeons track down often elusive, tiny parathyroid glands are timely topics for a new comprehensive textbook for endocrine surgeons. [More]
Scientists discover potential cure for triple negative breast cancer

Scientists discover potential cure for triple negative breast cancer

Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer." In laboratory experiments involving human cancer cells, scientists used a virus similar to the one that helped eradicate smallpox to coax cancer cells to produce a protein which makes them susceptible to radioactive iodine. [More]
New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins. [More]
Research roundup: Nursing home transitions; the impact of raising Medicare premiums; workers' views of job-based insurance

Research roundup: Nursing home transitions; the impact of raising Medicare premiums; workers' views of job-based insurance

Each week, KHN compiles a selection of recently released health policy studies and briefs. [More]
BMH-21 chemical compound has ability to shut down a common cancer process

BMH-21 chemical compound has ability to shut down a common cancer process

Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells. [More]